Online inquiry

IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5342MR)

This product GTTS-WQ5342MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5342MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ12659MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ7317MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ532MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ13863MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ7095MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ15770MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ5031MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW